PIPR Stock Recent News

Piper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as cleaner stores have allowed for trade-down benefits, but despite solid fundamentals, the set-up is "tricky" as the company likely has to raise the full year outlook to support shares at current levels, the analyst tells investors in a research note. 28 Aug

Piper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved as cleaner stores have allowed for trade-down benefits, but despite solid fundamentals, the set-up is "tricky" as the company likely has to raise the full year outlook to support shares at current levels, the analyst tells investors in a research note. 03 Sep

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too high. Summit is perceived as having the next Keytruda and as being a takeover candidate, but there is uncertainty around the reproducibility of the China datasets and lack of overall survival benefit seen to date, the analyst tells investors in a research note. As such, Piper prefers to wait for a better entry point.

Piper Sandler raised the firm's price target on Ormat Technologies to $90 from $78 and keeps a Neutral rating on the shares. Shares are up 33% year to date as the improving regulatory environment and demand for AI-related baseload power generation has driven a significant re-rating story, the analyst tells investors in a research note. 12 Dec

As previously reported, Piper Sandler initiated coverage of Janux Therapeutics with an Overweight rating and $42 price target. While noting that investor sentiment has waned over the course of 2025 following the announcement of completion of the JANX007 dose escalation and emergence of competitor clinical data, it continues to think JANX007 is "a differentiated, potentially best-in-class program" in metastatic castration-resistant prostate cancer. The firm views the recent stock pullback offering "an attractive entry point" ahead of clinical updates due later this year, the analyst added. 05 Dec

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confidence in daraxonrasib's second-line metastatic pancreatic ductal adenocarcinoma opportunity given the "highly encouraging" data presented to date. Piper sees share upside ahead of the first-line mPDAC data disclosure in the second half of 2025, which it believes could more than double the addressable patient population for daraxonrasib. 04 Dec

Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.

As previously reported, Piper Sandler initiated coverage of UroGen Pharma with an Overweight rating and $36 price target. Investors are starting to gain more confidence in the Zusduri launch, but the firm thinks the Street still underestimates peak sales potential in LG-IR-NMIBC and overestimates intellectual property risk to the -102/-103 franchise, the analyst contends. The firm sees early commercial launch datapoints, combined with updates from the Phase 3 UTOPIA trial of UGN-103, driving "meaningful upside" over the next 12-18 months. 26 Aug

Piper Sandler analyst Kelsey Goodwin initiated coverage of CG Oncology with an Overweight rating and $55 price target. The stock currently reflects low uptake in the initial high-risk Bacillus Calmette-Guerin nonmuscle invasive bladder cancer setting, and no value for label extensions, despite multiple shots on goal in additional NMIBC settings coming later this year, the analyst tells investors in a research note. 13 Dec

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the hiring of Toby AuWerter as a managing director in the merchant banking group. He will be based in the Minneapolis office. “We are very excited that Toby is joining the Piper Sandler merchant banking group. His operating, consulting and investing experience will prove valuable in augmenting our team's investment capabilities, especially in the healthcare sector. Toby will pla.